Citations

Clear

14 citation(s) found for "Chan, Kevin".

Characterization of Spirometric Response to Standard-of-care Treatment in Lung Allograft Recipients With Bronchiolitis Obliterans and the Utility of Spirometric Criteria for Rescue Therapy: Implications for the Design of Risk-stratified Clinical Trials
Hage, Chadi A. , Goldberg, Hilary J. , Patel, Mrunal, Reynolds, John M. , Klesney‐Tait, Julia , Arcasoy, Selim M. , Naik, Chetan , Simone, Nicole De , Usmani, Amena , Girgis, Reda E. , Cordova, Francis , Patil, Jagadish , Morrell, Matthew R. , Lendermon, Elizabeth A. , Huang, Howard J. , Peláez, Andrés, Emtazoo, Amir, Wille, Keith , Chan, Kevin M. , Yung, Gordon , Baz, M., Aryal, Shambhu , Derfler, Mary Clare, Commean, Paul K., Berman, Keith, Прокудин, А. В. , Despotis, George J. , Group, on the behalf of the EPI Study, Baz, Maher, Hachem, Ramsey R. , Byers, Derek E. , Walia, Rajat , Keller, Brian C. , Nunley, David R. , Baz, Maher, Vedantham, Suresh , Atkinson, Andrew , Atkinson, Jeffrey J. , Prokudin, Alexey, McCarthy, John Edward , Group, on the behalf of the EPI Study

Mayo Clinic

Transplantation | October 1, 2025 | Volume: 110 | Issue: 2 | Pages: e481-e491

10.1097/tp.0000000000005515 | PMID 41032890 Get It

Background. The spirometric response to standard-of-care (SOC) immunosuppressive therapy for the management of bronchiolitis obliterans syndrome (BOS) has been sparsely reported in the literature. Data from a Medicare-approved Registry were analyzed to characterize the effectiveness/durability of a wide range of SOC interventions to manage the decline of lung function and to validate the study spirometric criteria for initiation of rescue therapy. Methods. Lung transplant recipients with refractory BOS at 21 US collaborating centers were enrolled in the Registry. Data included both nonspirometric (eg, demographic, Immunosuppressive Regimens for management of BOS) and spirometric parameters (ie, forced expiratory volume in 1 s [FEV 1 ] measurements and derived indices). The utility of study FEV 1 criteria for treatment (ie, statistically significant rate of FEV 1 decline >30 mL/mo) was evaluated by comparing the spirometric course between participants who met or did not meet this criterion. Results. Only 21% of participants treated with SOC therapy had >50% decrease (76 ± 25% decrease) in the rate of FEV 1 decline. Although 51% of participants had a partial response (rate of FEV 1 decline decreased on average 71%), 49% of participants had a substantial increase (mean increase 224%). The FEV 1 criterion for treatment was able to identify 19% of participants (48/258) who achieved durable stabilization (ie, nonsignificant rate of FEV 1 <30 mL/mo) with SOC therapy. Conclusions. Patients with BOS have a widely variable response to SOC therapy. Our findings support the use of FEV 1 rate of decline to assess response to SOC therapy and to ensure appropriate assignment of participants with refractory BOS to rescue therapy treatment cohorts.
Identification of Surrogate Outcome Biomarkers in Lung Allograft Recipients With Bronchiolitis Obliterans: Implications for Randomized Controlled Trials
Hage, Chadi A. , Goldberg, Hilary J. , Patel, Mrunal, Reynolds, John M. , Klesney‐Tait, Julia , Arcasoy, Selim M. , Naik, Chetan , Simone, Nicole De , Usmani, Amena , Girgis, Reda E. , Cordova, Francis , Patil, Jagadish , Morrell, Matthew R. , Lendermon, Elizabeth A. , Huang, Howard J. , Peláez, Andrés, Emtazoo, Amir, Wille, Keith , Chan, Kevin M. , Yung, Gordon , Baz, M., Aryal, Shambhu , Derfler, Mary Clare, Commean, Paul K., Berman, Keith, Прокудин, А. В. , Despotis, George J. , Group, The EPI Study, Baz, Maher, Byers, Derek E. , Hachem, Ramsey R. , Walia, Rajat , Keller, Brian C. , Nunley, David R. , Baz, Maher, Vedantham, Suresh , Atkinson, Andrew , Atkinson, Jeffrey J. , Prokudin, Alexey, McCarthy, John Edward , Group, The EPI Study

Mayo Clinic

Transplantation Direct | September 19, 2025 | Volume: 11 | Issue: 10 | Pages: e1857

10.1097/txd.0000000000001857 | PMID 40989076 Get It

BACKGROUND. We developed a prospective, multicenter “registry” to evaluate the effect of extracorporeal photopheresis for lung transplant recipients who develop chronic lung allograft dysfunction (CLAD) with the bronchiolitis obliterans syndrome (BOS) phenotype (CLAD/BOS) and who are refractory to conventional standard-of-care therapy. METHODS. Data from 258 lung transplant recipients enrolled in the Registry between April 2015 and April 2022 were included in this analysis. All recorded parameters (eg, demographics), including forced expiratory volume in 1 s (FEV1) measurements and indices (FEV1% baseline, FEV1 rate of decline) at several time periods, were included in multivariate linear/logistic and Kaplan-Meier analyses to evaluate potential associations with survival. RESULTS. Mortality at 6 and 12 mo after CLAD/BOS diagnosis was 5% and 14%, whereas mortality at 6 and 12 mo after enrollment was 15% and 26%, respectively. The primary cause of death in the cohort was respiratory failure or graft failure (74%). Rate of FEV1 decline (log) at enrollment was independently associated with survival (log days) from CLAD/BOS diagnosis and enrollment (r = 0.55 and r = 0.3, respectively). The rates of FEV1 decline among survivors were lower (–77 ± 89 mL/mo) compared with nonsurvivors (–148 ± 155 mL/mo) at 6 mo after enrollment (P = 0.0001). CONCLUSIONS. The rate of FEV1 decline quantified using at least 5 FEV1 measurements is a robust surrogate outcome. We plan to use these findings to revise our randomized controlled trial to facilitate risk adjustment using FEV1 rate of decline strata at enrollment and as a scientifically valid surrogate for outcome.
Editorial for “Assessment of Intraocular Pressure Using Three‐Dimensional MR Elastography in Ophthalmologically Normal Individuals”
Murphy, Matthew C. , Chan, Kevin C. , Chan, Kevin C , Bang, Ji Won

Mayo Clinic

Journal of Magnetic Resonance Imaging | July 23, 2025 | Volume: 62 | Issue: 5 | Pages: 1494-1495

10.1002/jmri.70050 | PMID 40700642 Get It

Bladder Cancer, Version 3.2024
Flaig, Thomas W. , Abern, Michael, Agarwal, Neeraj , Bangs, Rick , Buyyounouski, Mark K. , Chang, Paul, Friedlander, Terence W. , Greenberg, Richard E. , Guru, Khurshid A. , Herr, Harry W., Hoffman‐Censits, Jean , Kaimakliotis, Hristos Z. , Kishan, Amar U. , Kundu, Shilajit , Lele, Subodh M. , Mamtani, Ronac , Michalski, Jeff M., Montgomery, Jeffrey S., Patterson, Anthony, Peyton, Charles C. , Preston, Mark A. , Sexton, Wade J. , Stewart, Tyler F. , Sundi, Debasish , Tollefson, Matthew K. , Wright, Jonathan L. , Cassara, Carly J., Gurski, Lisa A., Tollefson, Matthew, Spiess, Philippe E. , Agarwal, Neeraj , Chan, Kevin , Chang, Sam S. , Chang, Paul, Mian, Omar Y. , Parikh, Mamta , Plimack, Elizabeth R. , Richards, Kyle A. , Siefker-Radtke, Arlene Odelia , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 16, 2024 | Volume: 22 | Issue: 4 | Pages: 216-225

10.6004/jnccn.2024.0024 | PMID 38754471 Get It

Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non–muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer
Basourakos, Spyridon P. , An, Anjile , Davuluri, Meenakshi , Pinheiro, Laura C. , Awamlh, Bashir Al Hussein Al , Kensler, Kevin H. , Kensler, Kevin , Basourakos, Spyridon , Al Hussein Al Awamlh, Bashir , Borregales, Leonardo Daniel , Luan, Danny , Tamimi, Rulla M. , Hu, Jim C.

Mayo Clinic

Urology Practice | April 19, 2024 | Volume: 11 | Issue: 3 | Pages: 538-546

10.1097/upj.0000000000000529 | PMID 38640417 Get It

Abstract 3410: Financial toxicity among patients with advanced prostate cancer in the United States
Singh, Isani , Vaselkiv, Bailey, Enting, Deborah , Nowak, Joel , Kensler, Kevin H. , Nanus, David M. , Heath, Elisabeth I. , Kantoff, Phillip, Kaye, Deborah R. , George, Daniel J. , Mucci, Lorelei A. , Kensler, Kevin , Rencsok, Emily M. , Autio, Karen A. , Morgans, Alicia K. , Dreicer, Robert , Lewis, Brian E. , Sartor, Oliver , Kantoff, Phillip, George, Daniel J.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 3410-3410

10.1158/1538-7445.am2024-3410 Get It

Abstract Background: Advanced prostate cancer is defined as metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC). Newer and aggressive treatments are leading to increasing lifespans in this population. As such, studying quality of life could have a large impact on the survivorship experience. An important component of quality of life is financial toxicity, defined as the financial burden and distress that can arise for patients and their families because of cancer treatment. Objectives: To understand the prevalence and predictors of financial toxicity in advanced prostate cancer. Methods: IRONMAN (International Registry of Men with Advanced Prostate Cancer) is a prospective cohort of patients with newly diagnosed mHSPC or CRPC enrolling in 15 countries. Financial toxicity was collected using the EORTC QLQ-C30 (“has your physical condition or medical treatment caused you financial difficulties?”) at enrollment and every three months thereafter. For this analysis, we studied 997 patients cared for at 37 US sites enrolled from 7/2017 to 7/2023. We examined baseline and longitudinal reports of financial toxicity across clinical and demographic factors: age at enrollment, race and ethnicity, disease state, marital status, education, employment, military status, and type of health center. We conducted adjusted risk difference analysis and multivariable regression modeling to identify predictors of financial toxicity using a generalized estimating equations approach to calculate odds ratios (OR and 95% confidence intervals, CI). Results: At enrollment, 125 (13%) patients reported experiencing “quite a bit” or “very much” financial toxicity. 21% of Black patients experienced toxicity compared to 10% of White patients. Even after incorporating all other predictors, Black patients experienced 5% (95% CI: 0, 11) greater toxicity than White patients. Independently of other predictors, patients &gt;75 experienced 11% (CI: -17, -4) lower toxicity compared to those &lt;65 years (while patients in the 65-74 group experienced 6% less, CI: -12, 1). Toxicity was 6% greater in patients with mHSPC (CI: 2, 10) than in patients with CRPC, and disabled or unemployed patients were at substantially higher risk. In the multivariable longitudinal analyses, older age (&gt; 75) remained associated with significantly lower odds for financial toxicity (OR: 0.30, 0.15-0.61) while mHSPC (OR: 1.91, 1.14-3.20) and being unemployed (OR: 2.69, 1.03-6.99) or disabled (OR: 5.14, 2.29-11.6) were associated with higher odds. Conclusions: Financial toxicity is prevalent in advanced prostate cancer, especially in patients who are Black, younger than 75, diagnosed with mHSPC, or unemployed/disabled. These results may inform identification of patients at high risk for financial toxicity to support delivery of patient-situation-informed care by clinicians and targeted aid for patients at highest risk. Citation Format: Isani Singh, Bailey Vaselkiv, Emily Rencsok, Karen Autio, Deborah Enting, Alicia Morgans, Joel Nowak, Kevin Kensler, David Nanus, Robert Dreicer, Brian Lewis, Oliver Sartor, Elisabeth Heath, Phillip Kantoff, Deborah Kaye, Daniel George, Lorelei Mucci. Financial toxicity among patients with advanced prostate cancer in the United States [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3410.
Diverging patterns of plasticity in the nucleus basalis of Meynert in early- and late-onset blindness
Parra, Carlos , Murphy, Matthew C. , Schuman, Joel S. , Nau, Amy , Chan, Kevin C. , Schuman, Joel S , Chan, Kevin C , Bang, Ji Won , Chan, Russell W.

Mayo Clinic

Brain Communications | April 11, 2023 | Volume: 5 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcad119 | PMID 37101831 Get It

Abstract Plasticity in the brain is impacted by an individual’s age at the onset of the blindness. However, what drives the varying degrees of plasticity remains largely unclear. One possible explanation attributes the mechanisms for the differing levels of plasticity to the cholinergic signals originating in the nucleus basalis of Meynert. This explanation is based on the fact that the nucleus basalis of Meynert can modulate cortical processes such as plasticity and sensory encoding through its widespread cholinergic projections. Nevertheless, there is no direct evidence indicating that the nucleus basalis of Meynert undergoes plastic changes following blindness. Therefore, using multiparametric magnetic resonance imaging, we examined if the structural and functional properties of the nucleus basalis of Meynert differ between early blind, late blind and sighted individuals. We observed that early and late blind individuals had a preserved volumetric size and cerebrovascular reactivity in the nucleus basalis of Meynert. However, we observed a reduction in the directionality of water diffusion in both early and late blind individuals compared to sighted individuals. Notably, the nucleus basalis of Meynert presented diverging patterns of functional connectivity between early and late blind individuals. This functional connectivity was enhanced at both global and local (visual, language and default-mode networks) levels in the early blind individuals, but there were little-to-no changes in the late blind individuals when compared to sighted controls. Furthermore, the age at onset of blindness predicted both global and local functional connectivity. These results suggest that upon reduced directionality of water diffusion in the nucleus basalis of Meynert, cholinergic influence may be stronger for the early blind compared to the late blind individuals. Our findings are important to unravelling why early blind individuals present stronger and more widespread cross-modal plasticity compared to late blind individuals.
Feasibility of perioperative remote monitoring of patient‐generated health data in complex surgical oncology
Melstrom, Laleh G. , Zhou, Xiaoke , Kaiser, Andreas M. , Chan, Kevin , Lau, Clayton, Raoof, Mustafa , Zhumkhawala, Ali , Yuh, Bertram, Singh, Gagandeep , Fong, Yuman , Fong, Yuman , Melstrom, Laleh , Zhou, Xiaoke, Warner, Susanne G. , Sun, Virginia Chih-Yi

Mayo Clinic

Journal of Surgical Oncology | September 28, 2022 | Volume: 127 | Issue: 1 | Pages: 192-202

10.1002/jso.27106 | PMID 36169200 Get It

AbstractBackgroundThe feasibility of remote perioperative telemonitoring of patient‐generated physiologic health data and patient‐reported outcomes in a high risk complex general and urologic oncology surgery population is evaluated.MethodsComplex general surgical/urologic oncology patients wore a pedometer, completed ePROs (electronic patient‐reported outcome surveys) and record their vitals (weight, pulse, pulse oximetry, blood pressure, and temperature) via a telehealth app platform. Feasibility (% adherence) was assessed as the primary outcome measure.ResultsTwenty‐one patients with a median age 58 (32−82) years were included. The readmission rate was 33% and the incidence of ≥Grade 3a morbidity was 24%. Adherence to vital sign and ePRO measurements was 95% before surgery, 91% at discharge, and 82%, 68%, and 64% at postdischarge d2, 7, 14, and 30, respectively. There was significant worsening of mobility, self‐care and usual daily activity at postdischarge d2 compared to preoperative baseline (p < 0.05). Median daily preoperative steps taken by patients with <Grade 3a versus ≥Grade 3a postoperative morbidity was 6062 versus 4166 (p < 0.05). Of those interviewed, 87% (13/15) viewed vital sign devices as helpful in recovery.ConclusionsTelemonitoring is feasible in a general surgical and urologic oncology setting. Future studies will ascertain optimal patient selection, duration, and extent of perioperative monitoring.
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Flaig, Thomas W. , Abern, Michael, Agarwal, Neeraj , Bangs, Rick , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chan, Kevin , Friedlander, Terence W. , Greenberg, Richard E. , Guru, Khurshid A. , Herr, Harry W., Hoffman‐Censits, Jean , Kishan, Amar U. , Kundu, Shilajit , Lele, Subodh M. , Mamtani, Ronac , Margulis, Vitaly , Michalski, Jeff M., Montgomery, Jeffrey S., Nandagopal, Lakshminarayanan , Pagliaro, Lance C. , Patterson, Anthony, Pohar, Kamal S. , Preston, Mark A. , Sexton, Wade J. , Tollefson, Matthew K. , Wright, Jonathan L. , Dwyer, Mary A., Cassara, Carly J., Gurski, Lisa A., Tollefson, Matthew, Spiess, Philippe E. , Agarwal, Neeraj , Chang, Sam S. , Mian, Omar Y. , Parikh, Mamta , Plimack, Elizabeth R. , Richards, Kyle A. , Siefker-Radtke, Arlene Odelia , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 10, 2022 | Volume: 20 | Issue: 8 | Pages: 866-878

10.6004/jnccn.2022.0041 | PMID 35948037 Get It

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
Relationships between cerebrovascular reactivity, visual-evoked functional activity, and resting-state functional connectivity in the visual cortex and basal forebrain in glaucoma
Chan, Russell W. , Trivedi, Vivek, Murphy, Matthew C. , Wollstein, Gadi , Schuman, Joel S. , Schuman, Joel S , Bang, Ji Won , Liu, Peiying , Chan, Kevin C.

Mayo Clinic

2021 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) | December 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: 4037-4040

10.1109/embc46164.2021.9630904 | PMID 34892116 Get It